[{"from": "human", "value": "Provide a description of this molecule. [C][C][Branch1][C][C][Branch1][C][C][C][=N][C][=Branch2][Ring1][C][=C][Branch1][Ring2][S][Ring1][Branch1][C][=N][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][N][C][=C][Branch2][Ring1][=N][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][Branch1][Branch2][C][=C][C][=C][Ring1][=Branch1][F][18F][F]"}, {"from": "gpt", "value": "The molecule is a radioconjugate containing dabrafenib, a tyrosine kinase inhibitor of the V600 mutated version of the B-raf (BRAF) protein and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the dabrafenib moiety of fluorine F 18 dabrafenib specifically targets and binds to the BRAF V600-mutated form, expressed on tumor cells, thereby allowing the visualization of tumor cells expressing BRAF V600 upon PET. BRAF is constitutively activated in a variety of cancers due to BRAF gene mutations."}]